All In Biotech

Drug Trial Radar · NCT01918033

A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)

A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Aug 20, 2013

Primary completion

Jan 26, 2014

Study completion Jan 26, 2014

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • Desloratadine 5 mgDrug

    Desloratadine 5 mg tablets

  • PlaceboDrug

    Matching placebo to desloratadine 5 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2Time frame: Baseline and Week 2
  2. Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to Week 4
  3. Number of Participants Discontinuing Study Drug Due to an AETime frame: Up to Week 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.